About Agios Pharmaceuticals

We're focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. Our most advanced drug candidate is a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that is currently being evaluated for the treatment of three distinct hemolytic anemias. In addition to our active late-stage clinical pipeline, we have multiple novel, investigational therapies in clinical and preclinical development.

We’re a company that cares about our work, each other, and the people who are counting on us the most. We’re inspired to think big and welcome the different perspectives and backgrounds needed to deliver extraordinary results.

website icon
Website
employees icon
Employees
industry icon
Industry
Pharmaceuticals
location icon
Headquarter
88 Sidney Street, Cambridge, MA 02139, US
description icon
Founded
2008
description icon
Keywords
Biopharmaceuticals, Rare Genetic Diseases, Cellular Metabolism

Agios Pharmaceuticals Alternatives

Industry
Pharmaceuticals
Industry
Pharmaceuticals
Industry
pharmaceuticals
Industry
pharmaceuticals

Frequently Asked Questions about Agios Pharmaceuticals

Who is the CEO of Agios Pharmaceuticals?

David Schenkein is the CEO of Agios Pharmaceuticals.

Who are the decision makers in Agios Pharmaceuticals?

The decision makers in Agios Pharmaceuticals are Brian Goff, Brian Goff, Clive Patience, etc. Click to Find Agios Pharmaceuticals decision makers emails.

Supercharge your
Prospecting &
Outreach with
ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more